Iovance Biotherapeutics, Inc. (0JDK.L)
USD 3.56
(4.87%)
USD 3.56
(4.87%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -9.56 Million USD | 54.74% |
| 2022 | -21.13 Million USD | -51.18% |
| 2021 | -13.98 Million USD | -60.47% |
| 2020 | -8.71 Million USD | -7.25% |
| 2019 | -8.12 Million USD | -749.69% |
| 2018 | -956 Thousand USD | -0.42% |
| 2017 | -952 Thousand USD | 2.66% |
| 2016 | -978 Thousand USD | 2.1% |
| 2015 | -999 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -11.82 Million USD | 13.07% |
| 2024 Q2 | -262 Thousand USD | 97.78% |
| 2023 Q2 | -7.72 Million USD | -35.51% |
| 2023 Q3 | -9.74 Million USD | -26.17% |
| 2023 Q4 | -13.59 Million USD | -39.6% |
| 2023 Q1 | -5.69 Million USD | 0.18% |
| 2023 FY | -31.93 Million USD | -51.11% |
| 2022 Q4 | -5.7 Million USD | -9.71% |
| 2022 Q3 | -5.2 Million USD | 0.02% |
| 2022 Q2 | -5.2 Million USD | -4.52% |
| 2022 Q1 | -4.97 Million USD | -8.6% |
| 2022 FY | -21.13 Million USD | -51.18% |
| 2021 Q4 | -4.58 Million USD | 26.67% |
| 2021 Q1 | -2.65 Million USD | 0.0% |
| 2021 Q2 | -488 Thousand USD | 81.63% |
| 2021 FY | -13.98 Million USD | -60.47% |
| 2021 Q3 | -6.25 Million USD | -1180.94% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 FY | -8.71 Million USD | -7.25% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | -8.12 Million USD | -749.69% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | -956 Thousand USD | -0.42% |
| 2018 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | -952 Thousand USD | 2.66% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | -978 Thousand USD | 2.1% |
| 2016 Q2 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | -999 Thousand USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | 531.874% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 3267.55% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 88.774% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 155.234% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | -2956.23% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 164.661% |
| Imunon, Inc. | -720 Thousand USD | -1228.602% |
| Dynavax Technologies Corporation | 182.11 Million USD | 105.253% |
| Editas Medicine, Inc. | -99.52 Million USD | 90.389% |
| FibroGen, Inc. | 128.9 Million USD | 107.421% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -3057.096% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 100.518% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 100.875% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 101.826% |
| Verastem, Inc. | -62 Thousand USD | -15329.032% |
| Zoetis Inc. | 5.83 Billion USD | 100.164% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.111% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 78.895% |
| Homology Medicines, Inc. | -7.22 Million USD | -32.328% |
| Nektar Therapeutics | 53.47 Million USD | 117.888% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -3176.027% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 51.439% |
| Perrigo Company plc | 1.68 Billion USD | 100.569% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 113.092% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.036% |
| Illumina, Inc. | 2.74 Billion USD | 100.349% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.063% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 100.183% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 195.26% |
| Waters Corporation | 1.76 Billion USD | 100.543% |
| Biogen Inc. | 7.3 Billion USD | 100.131% |
| Evolus, Inc. | 140.52 Million USD | 106.807% |
| Adicet Bio, Inc. | -6.09 Million USD | -56.871% |
| bluebird bio, Inc. | -4.03 Million USD | -137.37% |
| Geron Corporation | -123.5 Million USD | 92.254% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 100.63% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 102.642% |
| Myriad Genetics, Inc. | 476.4 Million USD | 102.008% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 97.601% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 100.441% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 69.308% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 100.502% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.085% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 100.276% |
| OPKO Health, Inc. | 318.12 Million USD | 103.007% |
| Exelixis, Inc. | 1.75 Billion USD | 100.544% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 102.01% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 103.912% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 101.229% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 101.502% |
| Blueprint Medicines Corporation | 236.58 Million USD | 104.043% |
| Insmed Incorporated | 239.63 Million USD | 103.992% |
| TG Therapeutics, Inc. | 219.1 Million USD | 104.366% |
| Incyte Corporation | 3.44 Billion USD | 100.278% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 102.782% |